Search
ABT-737
go.drugbank.com/drugs/DB17023ExperimentalAn inhibitor of members of the Bcl‑2 family of apoptosis regulators.[A252977]
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalA prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … GC-376 is a 3C-like protease (3CL<sup>pro</sup> or M<sup>pro</sup>) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells
Timbetasin
go.drugbank.com/drugs/DB19119InvestigationalTimbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).
Synonyms: 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)thymosin .beta.4(human), Thymosin .beta.(4), 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)-MCC
go.drugbank.com/drugs/DB05282InvestigationalMycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
LX6171
go.drugbank.com/drugs/DB05180Investigationalis an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or
Bentracimab
go.drugbank.com/drugs/DB16659InvestigationalBentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or
GTS-21
go.drugbank.com/drugs/DB05708InvestigationalAthenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.
Itolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).